{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T10:04:07Z","timestamp":1783677847373,"version":"3.55.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Hematology"],"published-print":{"date-parts":[[2004,4,1]]},"DOI":"10.1532\/ijh97.03136","type":"journal-article","created":{"date-parts":[[2007,10,18]],"date-time":"2007-10-18T13:52:32Z","timestamp":1192715552000},"page":"283-288","source":"Crossref","is-referenced-by-count":24,"title":["Thalidomide-Induced Severe Neutropenia during Treatment of Multiple Myeloma"],"prefix":"10.1007","volume":"79","author":[{"given":"Yutaka","family":"Hattori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsunayuki","family":"Kakimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norihide","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuo","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"E00001","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0190-9622(96)90122-X","author":"Tseng, S","year":"1996","unstructured":"Tseng S, Pak G, Washenik K, Pomeranz MK, Shupak JL. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol. 1996;35:969-979.","journal-title":"J Am Acad Dermatol"},{"key":"E00002","doi-asserted-by":"crossref","first-page":"4082","DOI":"10.1073\/pnas.91.9.4082","author":"D'Amato, RJ","year":"1994","unstructured":"D'Amato RJ, Loughnan MS, Flynn E, Folkman J. Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A. 1994;91: 4082-4085.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"E00003","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1200\/JCO.2000.18.14.2710","author":"Baidas, SM","year":"2000","unstructured":"Baidas SM, Winer EP, Fleming GF, et al. Phase II evaluation of thalidomide in patients with metastatic breast cancer. J Clin Oncol. 2000;18:2710-2717.","journal-title":"J Clin Oncol"},{"key":"E00004","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1200\/JCO.2000.18.4.708","author":"Fine, HA","year":"2000","unstructured":"Fine HA, Figg WD, Jaeckle K, et al. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade glioma. J Clin Oncol. 2000;18:708-715.","journal-title":"J Clin Oncol"},{"key":"E00005","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1046\/j.1365-2141.2000.02239-11.x","author":"Gutheil, J","year":"2000","unstructured":"Gutheil J, Finucane D. Thalidomide therapy in refractory solid tumour patients. Br J Haematol. 2000;110:754.","journal-title":"Br J Haematol"},{"key":"E00006","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1111\/j.1365-2141.1994.tb08304.x","author":"Vacca, A","year":"1994","unstructured":"Vacca A, Ribiatti D, Roncali L, et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol. 1994;87:503-508.","journal-title":"Br J Haematol"},{"key":"E00007","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3109\/10428199509054750","author":"Vacca, A","year":"1995","unstructured":"Vacca A, Ribiatti D, Roncali L, Dommacco F. Angiogenesis in B cell lymphoproliferative diseases: biological and clinical studies. Leuk Lymphoma. 1995;20:27-38.","journal-title":"Leuk Lymphoma"},{"key":"E00008","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/ajh.2830500103","volume":"50","author":"Vacca, A","year":"1995","unstructured":"Vacca A, Loreto MD, Ribiatti D, et al. Bone marrow of patients with active myeloma: angiogenesis and plasma cell adhesion molecules LFA-1, VLA-4, LAM-1, and CD44. Am J Hematol. 1995;50:9-14.","journal-title":"Am J Hematol"},{"key":"E00009","doi-asserted-by":"crossref","first-page":"3064","DOI":"10.1182\/blood.V93.9.3064","volume":"93","author":"Vacca, A","year":"1999","unstructured":"Vacca A, Ribiatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 1999;93:3064-3073.","journal-title":"Blood"},{"key":"E00010","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1349-7006.2002.tb01278.x","author":"Sato, N","year":"2002","unstructured":"Sato N, Hattori Y, Du W, et al. Elevated level of plasma basic fibroblast growth factor in multiple myeloma correlates with increased disease activity. Jpn J Cancer Res. 2002;93:459-466.","journal-title":"Jpn J Cancer Res"},{"key":"E00011","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1365-2141.2003.03902.x","author":"Cavenagh, JD","year":"2003","unstructured":"Cavenagh JD, Oakervee H. Thalidomide in multiple myeloma: current status and future prospects. Br J Haematol. 2003;120:18-26.","journal-title":"Br J Haematol"},{"key":"E00012","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1007\/BF02983778","author":"Singhal, S","year":"2003","unstructured":"Singhal S, Mehta J. Novel therapies in multiple myeloma. Int J Hematol. 2003;77:226-231.","journal-title":"Int J Hematol"},{"key":"E00013","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0140-6736(05)75677-4","author":"Larkin, M","year":"1999","unstructured":"Larkin M. Low-dose thalidomide seems to be effective in multiple myeloma. Lancet. 1999;354:925.","journal-title":"Lancet"},{"key":"E00014","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","author":"Singhal, S","year":"1999","unstructured":"Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341: 1565-1571.","journal-title":"N Engl J Med"},{"key":"E00015","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0037-1963(00)90079-9","author":"Alexanian, R","year":"2000","unstructured":"Alexanian R, Weber D. Thalidomide for resistant and relapsing myeloma. Semin Hematol. 2000;37:22-25.","journal-title":"Semin Hematol"},{"key":"E00016","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1365-2141.2000.01983.x","author":"Juliusson, G","year":"2000","unstructured":"Juliusson G, Celsing F,Turesson I, Lenhoff S,Adriansson M, Malm C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma. Br J Haematol. 2000;109:89-96.","journal-title":"Br J Haematol"},{"key":"E00017","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1046\/j.1365-2141.2000.01835.x","author":"Kneller, A","year":"2000","unstructured":"Kneller A, Raanani P, Hardan I, et al. Therapy with thalidomide in refractory multiple myeloma patients: the revival of an old drug. Br J Haematol. 2000;108:391-393.","journal-title":"Br J Haematol"},{"key":"E00018","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V98.2.492","volume":"98","author":"Barlogie, B","year":"2001","unstructured":"Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood. 2001;98:492-494.","journal-title":"Blood"},{"key":"E00019","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1349-7006.2002.tb02480.x","volume":"93","author":"Kakimoto, T","year":"2002","unstructured":"Kakimoto T, Hattori Y, Okamoto S, et al.Thalidomide for the treatment of refractory multiple myeloma: association of plasma concentrations of thalidomide and angiogenic growth factors with clinical outcome. Jpn J Cancer Res. 2002;93:1029-1036.","journal-title":"Jpn J Cancer Res."},{"key":"E00020","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/sj.leu.2402183","volume":"15","author":"Rajkumar, SV","year":"2001","unstructured":"Rajkumar SV, Dispenzieri A, Fonseca R, et al.Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia. 2001;15:1274-1276.","journal-title":"Leukemia."},{"key":"E00021","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1182\/blood.V96.12.3995","volume":"96","author":"Koc, S","year":"2000","unstructured":"Koc S, Leisenring W, Flowers MED, et al.Thalidomide for treatment of patients with chronic graft-versus-host disease. Blood. 2000;96: 3995-3996.","journal-title":"Blood."},{"key":"E00022","doi-asserted-by":"crossref","first-page":"3604","DOI":"10.1182\/blood.V86.9.3604.bloodjournal8693604","volume":"86","author":"Parker, PM","year":"1995","unstructured":"Parker PM, Chao N, Nademanee A, et al.Thalidomide as salvage therapy for chronic graft-versus-host disease. Blood. 1995;86:3604-3609.","journal-title":"Blood."},{"key":"E00023","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","volume":"100","author":"Richardson, PG","year":"2002","unstructured":"Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood. 2002;100: 3063-3067.","journal-title":"Blood"},{"key":"E00024","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1200\/JCO.2002.20.1.302","author":"Motzer, RJ","year":"2002","unstructured":"Motzer RJ, Berg W, Ginsberg M, et al. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol. 2002; 20:302-306.","journal-title":"J Clin Oncol"},{"key":"E00025","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1200\/JCO.2002.20.1.302","author":"Motzer, RJ","year":"2002","unstructured":"Munshi N, Desikan KR,Anaissie E, et al. Peripheral blood stem cell collection after CAD+G-CSF as part of total therapy II in newly diagnosed multiple myeloma: influence of thalidomide administration [abstract]. Blood. 1999;94. Abstract 578a.","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1532\/IJH97.03136","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,25]],"date-time":"2021-08-25T22:41:41Z","timestamp":1629931301000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1532\/IJH97.03136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4,1]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2004,4,1]]}},"alternative-id":["55QXGPKYHGHQDCM5"],"URL":"https:\/\/doi.org\/10.1532\/ijh97.03136","relation":{},"ISSN":["0925-5710"],"issn-type":[{"value":"0925-5710","type":"print"}],"subject":[],"published":{"date-parts":[[2004,4,1]]}}}